NEW YORK (GenomeWeb) – Flagship Biosciences today said it is collaborating with Advanced Cell Diagnostics for the use of its RNAscope technology. 

Flagship said it is using ACD's technology to support ongoing CLIA-based clinical trials of its clients. Steve Potts, vice president of sales and marketing for Westminster, Colo.-based Flagship, told GenomeWeb in an email that his firm is using RNAscope and customizing and optimizing the technology for use in trials with "several large" undisclosed pharmaceutical clients. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The Wall Street Journal reports there is uncertainty surrounding whether He Jiankui's embryo editing did what he said it did.

Stat News reports that the pause on procuring fetal tissue for intramural US National Institutes of Health research will soon affect additional labs there.

Customers might want to consider what they might learn about their risk of diseases like Alzheimer's before snagging the genetic testing kits that are on many gift guides this year, NJ.com writes.

In Nature this week: genomic analysis of the invasive fall webworm, amp of constrained coding regions within the human genome, and more.